PMID- 22143936
OWN - NLM
STAT- MEDLINE
DCOM- 20120424
LR  - 20211021
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 16
IP  - 12
DP  - 2011
TI  - Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer 
      patients undergoing resection: a single-center study of 1,036 patients.
PG  - 1706-13
LID - 10.1634/theoncologist.2011-0199 [doi]
AB  - BACKGROUND: Opinions regarding the impact of human epidermal growth factor 
      receptor (HER)-2 overexpression or HER-2 amplification on the prognosis of 
      gastric cancer patients are mixed. The present study attempted to clarify this 
      issue by investigating a large cohort of surgical patients. METHODS: We 
      investigated 1,036 gastric cancer patients undergoing curative-intent resection. 
      Their surgical specimens were evaluated for HER-2 expression by 
      immunohistochemistry (IHC), and those with HER-2 expression levels of 2+ were 
      additionally subjected to fluorescence in situ hybridization (FISH). Data on 
      demographic and clinicopathological features and relevant prognostic factors in 
      these patients were analyzed. RESULTS: HER-2 positivity was noted in 64 (6.1%) of 
      1,036 gastric cancer patients, including 46 patients whose HER-2 expression level 
      was 3+ on IHC and 18 patients whose FISH results were positive. On univariate 
      analysis, HER-2 positivity was more often associated with differentiated 
      histology, intestinal type, and negative resection margins, whereas only 
      differentiated histology was independently associated with HER-2 positivity in a 
      logistic regression model. For stage I-IV gastric cancer, HER-2 was not a 
      prognostic factor. In a subpopulation study, although HER-2 positivity emerged as 
      a favorable prognostic factor for stage III-IV gastric cancer on univariate 
      analysis, it failed to be an independent prognostic factor after multivariate 
      adjustment. CONCLUSIONS: The prevalence of HER-2 positivity, determined using 
      standardized assays and scoring criteria in a large cohort of gastric cancer 
      patients after resection, was 6.1%. HER-2 positivity was phenotypically 
      associated with differentiated histology. HER-2 is not an independent prognostic 
      factor for gastric cancer.
FAU - Hsu, Jun-Te
AU  - Hsu JT
AD  - Department of Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung 
      University College of Medicine, Taoyuan, Taiwan.
FAU - Chen, Tse-Ching
AU  - Chen TC
FAU - Tseng, Jeng-Hwei
AU  - Tseng JH
FAU - Chiu, Cheng-Tang
AU  - Chiu CT
FAU - Liu, Keng-Hao
AU  - Liu KH
FAU - Yeh, Chun-Nan
AU  - Yeh CN
FAU - Hwang, Tsann-Long
AU  - Hwang TL
FAU - Jan, Yi-Yin
AU  - Jan YY
FAU - Yeh, Ta-Sen
AU  - Yeh TS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111205
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Aged
MH  - Cohort Studies
MH  - Female
MH  - Gastrectomy
MH  - *Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics/*metabolism
MH  - Stomach Neoplasms/diagnosis/*genetics/metabolism/surgery
PMC - PMC3248769
COIS- Disclosures: Jun-Te Hsu: None; Tse-Ching Chen: None; Jeng-Hwei Tseng: None; 
      Cheng-Tang Chiu: None; Keng-Hao Liu: None; Chun-Nan Yeh: None; Tsann-Long Hwang: 
      None; Yi-Yin Jan: None; Ta-Sen Yeh: None.
EDAT- 2011/12/07 06:00
MHDA- 2012/04/25 06:00
PMCR- 2012/12/01
CRDT- 2011/12/07 06:00
PHST- 2011/12/07 06:00 [entrez]
PHST- 2011/12/07 06:00 [pubmed]
PHST- 2012/04/25 06:00 [medline]
PHST- 2012/12/01 00:00 [pmc-release]
AID - theoncologist.2011-0199 [pii]
AID - 3737957 [pii]
AID - 10.1634/theoncologist.2011-0199 [doi]
PST - ppublish
SO  - Oncologist. 2011;16(12):1706-13. doi: 10.1634/theoncologist.2011-0199. Epub 2011 
      Dec 5.